BARDA Biomedical Advanced Research and Development Authority

BARDA, the Biomedical Advanced Research and Development Authority, sits in HHS and backs medical countermeasures and pandemic-preparedness work. The program is annual, grant-based, and scaled for US-based developers rather than nonprofits or individuals, with awards from $1 million to $500 million. Its mission is to support products that matter in a public-health emergency, not broad research curiosity. The record puts the median actual award around $15 million and the technical window at TRL 3 to 8. That makes it suitable for companies with real development programs in vaccines, therapeutics, diagnostics, or other emergency-response countermeasures. The scope cannot duplicate the same work elsewhere, and the support is available only to US-based for-profit applicants. Applicants do best when they can show a product path that matters in a public-health emergency and can survive the long development cycle required for regulated medical products. In practical terms, BARDA favors teams that can move from technical validation to scalable manufacture and deployment, with enough operating maturity to absorb large, staged awards.

No upcoming rounds verified. Cadence: Annual.